Identification

Name
Iron Dextran
Accession Number
DB00893  (APRD01053)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible.

Synonyms
  • Dextran iron
  • Iron dextran complex
External IDs
UNII-95HR524N2M
Active Moieties
NameKindUNIICASInChI Key
IronunknownE1UOL152H77439-89-6XEEYBQQBJWHFJM-UHFFFAOYSA-N
Ferric cationionic91O4LML61120074-52-6VTLYFUHAOXGGBS-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DexferrumInjection, solution50 mg/1mLIntravenousAmerican Regent1998-10-01Not applicableUs
DexferrumInjection, solution50 mg/1mLIntravenousAmerican Regent1996-03-01Not applicableUs
INFeDInjection50 mg/1mLIntramuscular; IntravenousActavis Pharma Company1974-04-29Not applicableUs
INFeDInjection50 mg/1mLIntramuscular; IntravenousAllergan, Inc.1974-04-29Not applicableUs
InfedInjection, solution50 mg/1mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-09-01Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
BiferaRxIron Dextran (22 mg/1) + Cyanocobalamin (25 ug/1) + Folic Acid (1 mg/1) + Heme iron polypeptide (6 mg/1)TabletOralMEDA Pharmaceuticals2012-10-312018-09-30Us
BiferaRxIron Dextran (22 mg/1) + Cyanocobalamin (25 ug/1) + Folic Acid (1 mg/1) + Heme iron polypeptide (6 mg/1)TabletOralAlaven Pharmaceutical2010-05-01Not applicableUs68220 0085 90 nlmimage10 2d1316d8
Iron Polysaccharides Folic Acid DHAIron Dextran (29 mg/1) + Ascorbic acid (30 mg/1) + Beta carotene (1100 [iU]/1) + Cholecalciferol (1000 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + DL-alpha tocopheryl acetate (20 mg/1) + Doconexent (200 mg/1) + Folic Acid (1 mg/1) + Magnesium oxide (20 mg/1) + Nicotinamide (15 mg/1) + Potassium Iodide (150 ug/1) + Pyridoxine hydrochloride (2.5 mg/1) + Riboflavin (1.8 mg/1) + Thiamine mononitrate (1.6 mg/1) + Zinc oxide (25 mg/1)Tablet, film coatedOralVirtus Pharmaceuticals2013-12-202013-12-30Us
Irospan 24/6Iron Dextran (65 mg/1) + Biotin (300 ug/1) + Biotin (300 ug/1) + Calcium Carbonate (100 mg/1) + Cyanocobalamin (10 ug/1) + Cyanocobalamin (10 ug/1) + Ferrous bisglycinate (65 mg/1) + Folic Acid (1 mg/1) + Folic Acid (1 mg/1) + Calcium formate (155 mg/1) + Niacin (25 mg/1) + Niacin (25 mg/1) + Calcium pantothenate (300 ug/1) + Calcium pantothenate (7 mg/1) + Pyridoxine hydrochloride (30 mg/1) + Pyridoxine hydrochloride (30 mg/1) + Riboflavin (5 mg/1) + Riboflavin (5 mg/1) + Sodium ascorbate (100 mg/1) + Sodium ascorbate (100 mg/1) + Succinic acid (150 mg/1) + Thiamine hydrochloride (5 mg/1) + Thiamine hydrochloride (5 mg/1)KitWomens Choice Pharmaceuticals, Llc2011-04-15Not applicableUs
NiferexIron Dextran (100 mg/1) + Ascorbic acid (60 mg/1) + Cyanocobalamin (25 ug/1) + Ferrous asparto glycinate (50 mg/1) + Folic Acid (250 ug/1) + Gastric intrinsic factor (100 mg/1) + Levomefolic acid (750 ug/1) + Succinic acid (50 mg/1) + Zinc (15 mg/1)TabletOralAvion Pharmaceuticals, Llc2017-01-23Not applicableUs
Prefera OB plus DHAIron Dextran (22 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate pentahydrate (0.8 mg/1) + Cyanocobalamin (12 ug/1) + Folic Acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (175 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.6 mg/1) + Selenium (65 ug/1) + Thiamine mononitrate (1.5 mg/1) + Zinc oxide (15 mg/1) + alpha-Tocopherol succinate (10 [iU]/1)TabletOralAlaven Pharmaceutical2009-04-01Not applicableUs
PreferaOBIron Dextran (28 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate pentahydrate (0.8 mg/1) + Cyanocobalamin (12 ug/1) + Folic Acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (250 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.6 mg/1) + Selenium (65 ug/1) + Thiamine mononitrate (1.5 mg/1) + Zinc oxide (4.5 ug/1) + alpha-Tocopherol succinate (10 [iU]/1)TabletOralAlaven Pharmaceutical2010-09-27Not applicableUs
PreferaOB OneIron Dextran (22 mg/1) + Ascorbic acid (25 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cyanocobalamin (12 ug/1) + DL-alpha tocopheryl acetate (10 [iU]/1) + Doconexent (200 mg/1) + Folic Acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (175 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Zinc oxide (15 ug/1)CapsuleOralAlaven Pharmaceutical2010-04-01Not applicableUs
PreferaOB plus DHAIron Dextran (28 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate pentahydrate (0.8 mg/1) + Cyanocobalamin (12 ug/1) + Folic Acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (250 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.6 mg/1) + Selenium (65 ug/1) + Thiamine mononitrate (1.5 mg/1) + Zinc oxide (4.5 ug/1) + alpha-Tocopherol succinate (10 [iU]/1)TabletOralAlaven Pharmaceutical2010-11-15Not applicableUs
PureFe OB PlusIron Dextran (53 mg/1) + Cupric sulfate pentahydrate (0.8 mg/1) + Cyanocobalamin (15 ug/1) + Ferrous fumarate (53 mg/1) + Folic Acid (1 mg/1) + Magnesium sulfate (6.9 mg/1) + Manganese sulfate (1.3 mg/1) + Nicotinamide (30 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (5 mg/1) + Riboflavin (6 mg/1) + Sodium ascorbate (200 mg/1) + Thiamine mononitrate (10 mg/1) + Zinc sulfate, unspecified form (18.2 mg/1)CapsuleOralPure Tek Corporation2011-06-01Not applicableUs
International/Other Brands
CosmoFer (B. Braun) / Dexferrum / Feosol (GlaxoSmithKline) / Imferon (Sanofi-Aventis) / Proferdex (New River Pharmaceuticals Inc.)
Categories
UNII
95HR524N2M
CAS number
9004-66-4
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

For treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Also used to replenish body iron stores in Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) patients receiving or not receiving erythropoietin and in Hemodialysis Dependent (HDD-CKD) and Peritoneal Dialysis Dependent (PDD-CKD) - Chronic Kidney Disease patients receiving an erythropoietin.

Associated Conditions
Pharmacodynamics

Iron dextran is a dark brown, slightly viscous sterile liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. It is for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Iron is essential to the formation of hemoglobin and to the function and formation of other heme and nonheme compounds. Untreated depletion of iron stores leads to iron-deficient erythropoiesis and, in turn, to iron deficiency anemia.

Mechanism of action

After iron dextran is injected, the circulating iron dextran is removed from the plasma by cells of the reticuloendothelial system, which split the complex into its components of iron and dextran. The iron is immediately bound to the available protein moieties to form hemosiderin or ferritin, the physiological forms of iron, or to a lesser extent to transferrin. This iron which is subject to physiological control replenishes hemoglobin and depleted iron stores.

TargetActionsOrganism
AHemoglobin subunit beta
activator
Human
AHemoglobin subunit alpha
activator
Human
AFerritin heavy chain
other
Human
AFerritin light chain
other
Human
Absorption

The major portion of intramuscular injections of iron dextran is absorbed within 72 hours; most of the remaining iron is absorbed over the ensuing 3 to 4 weeks.

Volume of distribution
Not Available
Protein binding

100% (after release from dextran)

Metabolism

Dextran, a polyglucose, is either metabolized or excreted.

Route of elimination

Dextran, a polyglucose, is either metabolized or excreted.

Half life

5 hours (some indications that it can be as long as 10 hours)

Clearance
Not Available
Toxicity

LD50 = 500 mg/kg (mouse, IV). Dosages of iron dextran in excess of the requirements for restoration of hemoglobin and replenishment of iron stores may lead to hemosiderosis. Cases of severe, sometimes fatal, allergic reactions (loss of consciousness, collapse, difficulty breathing, hives, swelling, or convulsions) and severe low blood pressure (hypotension) have been reported with the use of iron dextran.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic AcidThe risk or severity of adverse effects can be increased when 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid is combined with Iron Dextran.
3-Aza-2,3-Dihydrogeranyl DiphosphateIron Dextran can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Iron Dextran.
BenazeprilatThe risk or severity of adverse effects can be increased when Benazeprilat is combined with Iron Dextran.
Calcium PhosphateIron Dextran can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium phosphate dihydrateIron Dextran can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Iron Dextran.
CefdinirIron Dextran can cause a decrease in the absorption of Cefdinir resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Iron Dextran.
CinoxacinIron Dextran can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Food Interactions
Not Available

References

Synthesis Reference

William T. Monte, Laurie Scaggs, "Process for making crystalline iron dextran." U.S. Patent US5756715, issued 1905.

US5756715
General References
Not Available
External Links
KEGG Drug
D02141
PubChem Substance
46506136
ChEMBL
CHEMBL1201544
Therapeutic Targets Database
DAP001312
PharmGKB
PA164764618
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Iron_Dextran
MSDS
Download (45.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentPostpartum Anemia1
2CompletedTreatmentAnemias / Non-Myeloid Malignancies1
2CompletedTreatmentIron Deficiency Anemia (IDA)2
2CompletedTreatmentPregnancy1
3CompletedTreatmentAnemias1
4CompletedTreatmentTreatment of Iron Deficiency Anemia in Pregnancy1
4RecruitingTreatmentIron Deficiency Anemia of Pregnancy / Iron Malabsorption1
4SuspendedTreatmentIron Deficiency Anemia (IDA) / Perioperative Blood Conservation1
4TerminatedTreatmentAnemias1
4Unknown StatusTreatmentPreterm Anemia1
Not AvailableEnrolling by InvitationBasic ScienceIron Deficiency1

Pharmacoeconomics

Manufacturers
  • Luitpold pharmaceuticals inc
  • Watson laboratories inc
  • Sanofi aventis us llc
  • New river pharmaceuticals inc
Packagers
  • Alaven Pharmaceutical
  • American Regent
  • General Injectables and Vaccines Inc.
  • Gensavis LLC
  • Luitpold Pharmaceuticals Inc.
  • Patheon Inc.
  • Physicians Total Care Inc.
  • Primedics Laboratories
  • Schein Pharmaceutical Inc.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
Injection, solutionIntravenous50 mg/1mL
InjectionIntramuscular; Intravenous50 mg/1mL
Injection, solutionIntramuscular; Intravenous50 mg/1mL
Tablet, film coatedOral
Kit
TabletOral
CapsuleOral
Capsule, gelatin coatedOral
Prices
Unit descriptionCostUnit
Iron dextran comp 100 mg/2 ml38.08USD ml
Dexferrum 100 mg/2 ml vial21.6USD ml
Dexferrum 50 mg/ml vial21.6USD ml
Dexiron 50 mg/ml15.66USD ml
Infufer 50 mg/ml15.53USD ml
Infed 100 mg/2 ml vial14.44USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5624668No1997-04-292015-09-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Activator
General Function
Oxygen transporter activity
Specific Function
Involved in oxygen transport from the lung to the various peripheral tissues.LVV-hemorphin-7 potentiates the activity of bradykinin, causing a decrease in blood pressure.Spinorphin: functions as an...
Gene Name
HBB
Uniprot ID
P68871
Uniprot Name
Hemoglobin subunit beta
Molecular Weight
15998.34 Da
References
  1. Zaric J, Lazic D, Markovic S, Glisin V, Ivanovic Z, Milenkovic P, Popovic Z: Alpha- and beta-globins of the anemic Belgrade laboratory rat. II. The effect of hemin and iron-dextran treatment. Hemoglobin. 1998 May;22(3):231-44. [PubMed:9629498]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Activator
General Function
Oxygen transporter activity
Specific Function
Involved in oxygen transport from the lung to the various peripheral tissues.
Gene Name
HBA1
Uniprot ID
P69905
Uniprot Name
Hemoglobin subunit alpha
Molecular Weight
15257.405 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Other
General Function
Iron ion binding
Specific Function
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after ...
Gene Name
FTH1
Uniprot ID
P02794
Uniprot Name
Ferritin heavy chain
Molecular Weight
21225.47 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Other
General Function
Iron ion binding
Specific Function
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a ro...
Gene Name
FTL
Uniprot ID
P02792
Uniprot Name
Ferritin light chain
Molecular Weight
20019.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transferrin receptor binding
Specific Function
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from si...
Gene Name
TF
Uniprot ID
P02787
Uniprot Name
Serotransferrin
Molecular Weight
77063.195 Da
References
  1. Macdougall IC: Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999 Mar;69:S61-6. [PubMed:10084288]
  2. Salahudeen AK, Oliver B, Bower JD, Roberts LJ 2nd: Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int. 2001 Oct;60(4):1525-31. [PubMed:11576368]
  3. Pai AB, Boyd AV, McQuade CR, Harford A, Norenberg JP, Zager PG: Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy. 2007 Mar;27(3):343-50. [PubMed:17316146]
  4. Jacobs JC, Alexander NM: Colorimetry and constant-potential coulometry determinations of transferrin-bound iron, total iron-binding capacity, and total iron in serum containing iron-dextran, with use of sodium dithionite and alumina columns. Clin Chem. 1990 Oct;36(10):1803-7. [PubMed:2208657]
  5. Speyer BE, Doney VJ, Fielding J: Transfer of iron from Ferastral and other organic complexes to transferrin as measured by reticulocyte uptake. Scand J Haematol Suppl. 1977;32:215-21. [PubMed:272031]

Drug created on June 13, 2005 07:24 / Updated on November 02, 2018 04:52